At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PLSE Pulse Biosciences
Market Closed 02-27 16:00:00 EST
18.73
-0.56
-2.90%
盘后18.36
-0.37-1.98%
19:36 EST
High19.57Low18.54Vol166.27K
Open18.94D1 Closing19.29Amplitude5.35%
Mkt Cap1.27BTradable Cap326.62MTotal Shares67.77M
T/O3.13MT/O Rate0.95%Tradable Shares17.44M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Pulse Biosciences (PLSE) Is Down 12.6% After Wider Losses And New Funding Plans - Has The Bull Case Changed?
Simply Wall St.  ·  02-28 17:28
Pulse Biosciences (PLSE) Is Down 12.6% After Wider Losses And New Funding Plans - Has The Bull Case Changed?
Pulse Biosciences Announces Resignation of Chief Commercial Officer
TIPRANKS  ·  02-28 06:52
Pulse Biosciences Announces Resignation of Chief Commercial Officer
Pulse Biosciences Chief Commercial Officer Kevin P. Danahy Resigns Immediately
Reuters  ·  02-28 06:27
Pulse Biosciences Chief Commercial Officer Kevin P. Danahy Resigns Immediately
Pulse Biosciences Chief Commercial Officer Kevin Patrick Danahy Disposes of Common Shares
Reuters  ·  02-24
Pulse Biosciences Chief Commercial Officer Kevin Patrick Danahy Disposes of Common Shares
Pulse Biosciences Grants 19,000 Inducement Stock Options to New Hires
Reuters  ·  02-21
Pulse Biosciences Grants 19,000 Inducement Stock Options to New Hires
Stock Track | Pulse Biosciences Plummets 5.06% Intraday as Profit-Taking Follows Strong Quarterly Gains Despite Earnings Beat
Stock Track  ·  02-20
Stock Track | Pulse Biosciences Plummets 5.06% Intraday as Profit-Taking Follows Strong Quarterly Gains Despite Earnings Beat
Pulse Biosciences Inc. : Oppenheimer Raises Target Price to $30 From $22
THOMSON REUTERS  ·  02-20
Pulse Biosciences Inc. : Oppenheimer Raises Target Price to $30 From $22
Mizuho Securities Sticks to Their Buy Rating for Pulse Biosciences (PLSE)
TIPRANKS  ·  02-20
Mizuho Securities Sticks to Their Buy Rating for Pulse Biosciences (PLSE)
Pulse Biosciences to Present at TD Cowen Healthcare Conference
Reuters  ·  02-20
Pulse Biosciences to Present at TD Cowen Healthcare Conference
BRIEF-Pulse Biosciences Says It Enters Equity Distribution Agreement With TD Securities
Reuters  ·  02-20
BRIEF-Pulse Biosciences Says It Enters Equity Distribution Agreement With TD Securities
Pulse Biosciences Establishes New $60 Million ATM Program
TIPRANKS  ·  02-20
Pulse Biosciences Establishes New $60 Million ATM Program
Pulse Biosciences Inc - to Offer Securities Worth $200 Mln - SEC Filing
THOMSON REUTERS  ·  02-20
Pulse Biosciences Inc - to Offer Securities Worth $200 Mln - SEC Filing
Pulse Biosciences Inc - Enters Equity Distribution Agreement With TD Securities - SEC Filing
THOMSON REUTERS  ·  02-20
Pulse Biosciences Inc - Enters Equity Distribution Agreement With TD Securities - SEC Filing
Pulse Biosciences Inc - May Sell Shares Worth up to About $60 Mln - SEC Filing
THOMSON REUTERS  ·  02-20
Pulse Biosciences Inc - May Sell Shares Worth up to About $60 Mln - SEC Filing
Pulse Biosciences posts FY 2025 GAAP net loss of USD 72.8 million (+36%)
Reuters  ·  02-20
Pulse Biosciences posts FY 2025 GAAP net loss of USD 72.8 million (+36%)
Pulse Biosciences Q4 EPS $(0.26) Beats $(0.31) Estimate, Sales $264.000K Beat $250.000K Estimate
Benzinga  ·  02-20
Pulse Biosciences Q4 EPS $(0.26) Beats $(0.31) Estimate, Sales $264.000K Beat $250.000K Estimate
BRIEF-Pulse Biosciences Q4 Income From Operations USD -18.253 Million
Reuters  ·  02-20
BRIEF-Pulse Biosciences Q4 Income From Operations USD -18.253 Million
Pulse Biosciences Q4 Net Income USD -17.433 Million
THOMSON REUTERS  ·  02-20
Pulse Biosciences Q4 Net Income USD -17.433 Million
Pulse Biosciences Chief Commercial Officer Kevin Patrick Danahy Reports Disposal of Common Shares
Reuters  ·  02-18
Pulse Biosciences Chief Commercial Officer Kevin Patrick Danahy Reports Disposal of Common Shares
Earning Preview: Pulse Biosciences this quarter’s revenue is expected to increase by 0%, and institutional views are bullish
Earnings Agent  ·  02-12
Earning Preview: Pulse Biosciences this quarter’s revenue is expected to increase by 0%, and institutional views are bullish

Introduction

Company Name.
Pulse Biosciences
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. The company was incorporated in 2014 and is headquartered in Hayward, California.
Issue price:
--